- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04045847
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
May 6, 2020 updated by: Xijing Hospital
A Clinical Study to Investigate the Safety, Tolerance and Efficacy Evaluation of Single-centre, Open-label of Local Treatment of CD147-CART in Recurrent Glioblastoma.
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients autologous T cells are activated and then engineered to express chimeric antigen receptors (CARs) specific for CD147(CD147-CART).
CAR-T cells are expanded in culture and returned to the patient by Ommaya Reservoir at specific cell doses.
Three CD147-CART doses patient are planned at 1-week intervals.
Serum cytokine level and CAR-T cell number will be measured in whole treatment session.
Study Type
Interventional
Enrollment (Anticipated)
31
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhinan Chen, PhD
- Phone Number: 029-84774547
- Email: znchen@fmmu.edu.cn
Study Contact Backup
- Name: Zhou Fei, Dr
- Phone Number: 029-84775323
- Email: feizhou@fmmu.edu.cn
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- National Translational Science Center for Molecular Medicine & Department of Cell Biology
-
Contact:
- Zhinan Chen, PhD
- Email: znchen@fmmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 year and ≤ 65 years, both male and female;
- Recurrent glioblastoma patients confirmed by histology or cytology, which have received standard care of STUPP protocol (TMZ concurrent chemoradiotherapy and adjuvant chemotherapy protocol) after surgery;
- Cerebral ventricle was not opened after glioma surgery;
- More than 6 months after the first glioma surgery;
- Tumor lesions that can be evaluated or measured according to RANO criteria (Measurable enhancement lesions were defined as enhancement lesions with clear upper boundary of CT or MRI, capable of developing on ≥2 axial films with layer thickness of 5 mm, and the length and diameter of each other were >10 mm. If the scanning layer thickness is large, the minimum measurable lesion should be >2 times thick);
- CD147+ was confirmed by histologically diagnosis (IHC staining).
- Adequate PBMC can be obtained according to the requirements of cell preparation, and there are no other contraindications for lymphocyte collection;
- KPS score ≥70;
- Patient with a life expectancy of greater than three months;
- Patients with entirely informed consent and voluntarily sign the informed consent by themselves or their legal representative.
Exclusion Criteria:
- Patients who have received radiotherapy after recurrence;
- Patients who have received corticosteroids or other immunosuppressive agents in the past 2 weeks;
- Patients who have received live vaccine in the past 4 weeks and/or plan to receive live vaccine after participating in the trial;
- Patients who have received chemotherapy in addition to lymphocyte clearance in the past 2 weeks;
- Patients who have not recover from adverse events caused by previous anti-tumor therapy (≤1 according to CTCAE v5.0) prior to enrollment, except for hair loss;
- Patients who have received gene therapy, cell therapy or immune therapy;
- Patients who have received organ transplantation;
- Patients who cannot able to perform craniocerebral MRI examination;
Patients with following abnormalities:
- Absolute neutrophil count (ANC)<1.5×109/L, platelet (PLT)<80×109/L or hemoglobin(HGB)<100 g/dL;
- Prothrombin time (PT), activated partial thromboplastin time (APTT) or international normalized ratio (INR) > 1.5×ULN (upper normal value);
- Total bilirubin(TBIL) > 2×ULN; ALT, AST or ALP>3×ULN;
- Serum creatinine (Cr)≥1.5×ULN or glomerular filtration rate (GFR) < 60mL/min×1.73m2;
- Syphilis test (TRUST) positive, Anti-HIV positive, Anti-HCV positive with HCV-RNA level higher than the lower limit of detection (LOD), or HBcAb positive with HBV-DNA level higher than the LOD;
- Left ventricular ejection fraction (LVEF) < 50%;
- An acute bacterial or fungal infection that requires intravenous antibiotics during CAR-T cell therapy;
- Patients who presented with negligent compensatory heart failure (NYHA grade III and IV), unstable angina pectoris, acute myocardial infarction, persistent and clinically significant arrhythmia within 3 months;
- Patients who requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks;
- Patients with other malignant tumors that have not been effectively controlled within the past five years;
- Patients who suffering from tuberculosis and not cured;
- Patients with a history of allergic reactions attributed to any agents or compounds involved in this study;
- Patients allergic to contrast agents;
- Patients with a history of mental disorders;
- Patients with a history of drug abuse;
- Pregnant and lactating women, or planning to become pregnant during the study;
- Patients of childbearing age who unwilling or unable to use effective and adequate contraception during and 3 months after the study;
- Patients who enrolled in other clinical trials within 30 days;
- Patients who were considered not suitable for this clinical trial by investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CD147-CART
CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks
|
Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and type of adverse events induced by CD147-CART
Time Frame: 12 weeks
|
To assess the safety and tolerability of CD147-CART (anti-CD147 CAR-T cell) for glioma which measured by number and type of adverse events.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLT and MTD of CD147-CART cell
Time Frame: 12 weeks
|
To determine the dose limited toxicity (DLT) and maximum tolerated dose (MTD) of CD147-CART.
|
12 weeks
|
Clinical Activity of CD147-CART cell
Time Frame: 2 years
|
To evaluate treatment response of CD147-CART for glioma
|
2 years
|
CD147-CART detection in Peripheral Blood
Time Frame: 2 years
|
Quantification of CD147-CART cells in blood samples.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 30, 2019
Primary Completion (ANTICIPATED)
October 30, 2020
Study Completion (ANTICIPATED)
May 30, 2022
Study Registration Dates
First Submitted
August 4, 2019
First Submitted That Met QC Criteria
August 4, 2019
First Posted (ACTUAL)
August 6, 2019
Study Record Updates
Last Update Posted (ACTUAL)
May 7, 2020
Last Update Submitted That Met QC Criteria
May 6, 2020
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Chen Zhinan-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
Clinical Trials on CD147-CART
-
Xijing HospitalUnknownAdvanced Hepatocellular CarcinomaChina
-
Sinotau Pharmaceutical GroupNot yet recruiting
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
University of PennsylvaniaNovartisActive, not recruitingMultiple MyelomaUnited States
-
University of Southern CaliforniaCompleted
-
Chinese University of Hong KongNot yet recruiting
-
Shanghai Unicar-Therapy Bio-medicine Technology...RecruitingAcute Myeloid LeukemiaChina
-
Shanghai Simnova Biotechnology Co.,Ltd.Active, not recruitingMultiple MyelomaChina
-
University of PennsylvaniaTerminatedLYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)United States
-
Laboratoires ArkopharmaCompleted